This article is more than 5 years old. Information may no longer be current.

VIDEO: Statin intolerance a ‘real phenomenon’

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — In this video exclusive, Steven E. Nissen, MD, presents results of the GAUSS-3 trial, which investigated LDL reduction with evolocumab compared with ezetimibe in patients with statin intolerance.

The GAUSS-3 trial was designed to gain a more thorough understanding of patients with statin intolerance, according to Nissen, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Cleveland Clinic’s Sydell and Arnold Miller Family Heart and Vascular Institute. The study was conducted in two double blind phases to evaluate the efficacy and tolerability of the PCSK9 inhibitor (Repatha, Amgen) compared with ezetimibe (Zetia, Merck) in patients with muscle-related statin intolerance during 24 weeks of follow-up.

Based on the results presented at the American College of Cardiology Scientific Session, “we learned that statin intolerance is a real phenomenon,” Nissen said. “It can be confirmed in about 40% of patients with a strong history [of statin intolerance] and that they can achieve good LDL levels when treated with a PCSK9 inhibitor.”